GlassScriptPhysician profile
Edward S Deutsch
NPI 1457337883
$13,480.22
in general payments reported to CMS, 2019-2025
44 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $1,344 · 2021: $1,833 · 2022: $2,349 · 2023: $2,189 · 2024: $1,933 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,729 · Education: $47.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,729.35 |
| Education | $47.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,124.90 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,564.53 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,385.10 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $754.33 | 2019-2023 | Trulance |
| Genzyme Corporation | $512.54 | 2022-2025 | |
| Celgene Corporation | $441.56 | 2019-2024 | Zeposia |
| Ardelyx, INC. | $390.34 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $246.01 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $244.01 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $234.00 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $231.83 | 2019-2025 | |
| Ucb, INC. | $201.42 | 2019-2020 | |
| Lilly USA, LLC | $201.41 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $176.39 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $156.15 | 2024-2025 | Zenpep |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Deutsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.